PlainRecalls
FDA Drug Low Class III Terminated

Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-12) and b) 5- Single-Use Containers (NDC 0078-0911-05) Rx Only, Manufactured by: The Ritedose Corporation, Columbia, SC 29203, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.

Reported: June 15, 2022 Initiated: May 10, 2022 #D-0982-2022

Product Description

Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-12) and b) 5- Single-Use Containers (NDC 0078-0911-05) Rx Only, Manufactured by: The Ritedose Corporation, Columbia, SC 29203, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.

Reason for Recall

Failed Impurities/Degradation Specifications.

Details

Units Affected
1,187,092 vials
Distribution
Nationwide within the United States
Location
East Hanover, NJ

Frequently Asked Questions

What product was recalled?
Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-12) and b) 5- Single-Use Containers (NDC 0078-0911-05) Rx Only, Manufactured by: The Ritedose Corporation, Columbia, SC 29203, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.. Recalled by Novartis Pharmaceuticals Corporation. Units affected: 1,187,092 vials.
Why was this product recalled?
Failed Impurities/Degradation Specifications.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 15, 2022. Severity: Low. Recall number: D-0982-2022.